Home/Pipeline/FMR1 Program

FMR1 Program

Fragile X Syndrome (FXS)

DiscoveryActive

Key Facts

Indication

Fragile X Syndrome (FXS)

Phase

Discovery

Status

Active

Company

Quiver Bioscience

About Quiver Bioscience

Quiver Bioscience is a private, pre-clinical stage biotech leveraging a proprietary, integrated platform of human disease models, scalable neural measurement technology, and AI to tackle the high failure rates in neurological drug development. The company has built a pipeline of wholly-owned antisense oligonucleotide (ASO) programs targeting genetically-validated pathways in chronic pain and developmental epileptic encephalopathies, and has secured strategic research collaborations with pharmaceutical partners. Positioned at the intersection of genetics, scalable biology, and computational power, Quiver aims to become a premier partner in translating target discovery into clinical candidates for CNS disorders.

View full company profile

Therapeutic Areas

Chronic Pain Developmental and Epileptic Encephalopathy Dup15q Syndrome Fragile X Syndrome Tuberous Sclerosis

Other Fragile X Syndrome (FXS) Drugs

Drug	Company	Phase	Status
CTH120	Connecta Therapeutics	Phase 2 (Preparation)	Active
Fragile X Syndrome Candidate	Shionogi	Phase 3	Active